DLC1: A significant GAP in the cancer genome

79Citations
Citations of this article
63Readers
Mendeley users who have this article in their library.

Abstract

Rho GTPases are believed to make important contributions to the development and progression of human cancer, but direct evidence in the form of somatic mutations analogous to those affecting Ras has been lacking. A recent study in Genes & Development by Xue and colleagues (pp. 1439-1444) now provides in vivo evidence that DLC1, a negative regulator of Rho, is a tumor suppressor gene deleted almost as frequently as p53 in common cancers such as breast, colon, and lung. © 2008 by Cold Spring Harbor Laboratory Press.

Author supplied keywords

Cite

CITATION STYLE

APA

Lahoz, A., & Hall, A. (2008, July 1). DLC1: A significant GAP in the cancer genome. Genes and Development. https://doi.org/10.1101/gad.1691408

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free